CIK 0001829802 · <br>Emerging growth company
Faeth Therapeutics, Inc.
Sign in to watch- Ticker
- FTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 512-200-2982
- Business address
- 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
- Former names
- Sensei Biotherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-15 | van der Horst Edward Chief Scientific Officer | Grant or award | +17,700 | 62,438 | ||
| 2023-02-15 | van der Horst Edward Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-02-15 | Colgan Erin Chief Financial Officer | Grant or award | +30,046 | 51,732 | ||
| 2023-02-15 | Colgan Erin Chief Financial Officer | Grant or award | +21,300 | 73,032 | ||
| 2023-02-15 | Colgan Erin Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Grant or award | +29,313 | 29,313 | ||
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Grant or award | +14,200 | 43,515 | ||
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2023-02-15 | Celebi John President and CEO | Grant or award | +51,893 | 106,007 | ||
| 2023-02-15 | Celebi John President and CEO | Grant or award | +21,300 | 127,307 | ||
| 2023-02-15 | Celebi John President and CEO | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2022-06-10 | Cambrian BioPharma Inc 10% owner | Grant or award | +4,466 | 5,235,956 | ||
| 2022-06-10 | Cambrian BioPharma Inc 10% owner | Grant or award · Stock Option (right to buy) | +14,550 | 14,550 | ||
| 2022-06-10 | Peyer James Director | Grant or award | +4,466 | 5,235,956 | ||
| 2022-06-10 | Peyer James Director | Grant or award · Stock Option (right to buy) | +14,550 | 14,550 | ||
| 2022-06-10 | Cambrian BioPharma Inc 10% owner | Grant or award | +4,466 | 5,235,954 | ||
| 2022-06-10 | Cambrian BioPharma Inc 10% owner | Grant or award · Stock Option (right to buy) | +14,550 | 14,550 | ||
| 2022-06-10 | Peyer James Director | Grant or award | +4,466 | 5,235,954 | ||
| 2022-06-10 | Peyer James Director | Grant or award · Stock Option (right to buy) | +14,550 | 14,550 | ||
| 2022-06-10 | Vojta Deneen Director | Grant or award | +4,466 | 4,466 |
Page 11 of 12 · 238 trades